ArticleBritish journal of pharmacology2017
Combination therapy with telmisartan and parecoxib induces regression of endometriotic lesions.
Article in British journal of pharmacology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 19 citations in OpenAlex.
- Causal Effects of Endometriosis Stages on Adverse Pregnancy and Perinatal Outcomes: A Mendelian Randomization Study.International journal of women's health · 2025Article
- Catamenial Pneumothorax-Still an Unveiled Disease.Medicina (Kaunas, Lithuania) · 2024Review
- Angiogenesis signaling in endometriosis: Molecules, diagnosis and treatment (Review).Molecular medicine reports · 2024Review
- The role of peroxisome proliferator-activated receptors in endometriosis.Frontiers in medicine · 2024Review
- Telmisartan-Loaded Lactosylated Chitosan Nanoparticles as a Liver Specific Delivery System: Synthesis, Optimization and Targeting Efficiency.AAPS PharmSciTech · 2023Article
- Endometriosis and cardiovascular disease.European heart journal open · 2022Article
- Article
- Endometriosis: current challenges in modeling a multifactorial disease of unknown etiology.Journal of translational medicine · 2020Review
- New therapeutic approaches for endometriosis besides hormonal therapy.Chinese medical journal · 2019Review
- Cyclooxygenase-2 in Endometriosis.International journal of biological sciences · 2019Review
- Combination therapy with telmisartan and parecoxib induces regression of endometriotic lesions.British journal of pharmacology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background and purposeTelmisartan suppresses the development of endometriotic lesions. However, the drug also up-regulates the expression of COX-2, which has been suggested to promote the progression of endometriosis. Accordingly, in the present study we analysed whether a combination therapy with telmisartan and a COX-2 inhibitor may be more effective in the treatment of endometriotic lesions than the application of telmisartan alone. EXPERIMENTAL APPROACH: Endometriotic lesions were induced in the peritoneal cavity of C57BL/6 mice, which were treated daily with an i.p. injection of telmisartan (10 mg·kg KEY
resultsTelmisartan-treated lesions exhibited a significantly reduced lesion volume when compared with vehicle-treated controls and parecoxib-treated lesions. This inhibitory effect of telmisartan was even more pronounced when it was used in combination with parecoxib. The combination therapy resulted in a reduced microvessel density as well as lower numbers of proliferating Ki67-positive cells and higher numbers of apoptotic cleaved caspase-3-positive stromal cells within the lesions. This was associated with a lower expression of COX-2, MMP-9 and p-Akt/Akt when compared with controls. The application of the two drugs further inhibited the ingrowth of nerve fibres into the lesions. CONCLUSIONS AND IMPLICATIONS: Combination therapy with telmisartan and a COX-2 inhibitor represents a novel, effective pharmacological strategy for the treatment of endometriosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.